NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Receives Average Recommendation of “Moderate Buy” from Analysts

NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) has earned an average recommendation of “Moderate Buy” from the six brokerages that are currently covering the company, Marketbeat reports. One investment analyst has rated the stock with a sell recommendation, one has assigned a hold recommendation and four have issued a buy recommendation on the company. The average twelve-month price objective among brokers that have updated their coverage on the stock in the last year is $38.00.

A number of equities research analysts have issued reports on the company. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of NRx Pharmaceuticals in a research report on Monday, December 29th. Wall Street Zen raised NRx Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Sunday, November 23rd. Ascendiant Capital Markets restated a “buy” rating and set a $48.00 target price (up from $47.00) on shares of NRx Pharmaceuticals in a research note on Friday, January 2nd. D. Boral Capital reaffirmed a “buy” rating and issued a $34.00 target price on shares of NRx Pharmaceuticals in a report on Monday. Finally, Zacks Research upgraded shares of NRx Pharmaceuticals from a “strong sell” rating to a “hold” rating in a research note on Monday, March 2nd.

NRx Pharmaceuticals Trading Down 6.3%

NASDAQ:NRXP opened at $1.95 on Wednesday. The firm has a market cap of $62.15 million, a PE ratio of -0.83 and a beta of 1.97. The stock has a fifty day moving average price of $1.98 and a 200 day moving average price of $2.46. NRx Pharmaceuticals has a 12-month low of $1.58 and a 12-month high of $3.84.

Institutional Investors Weigh In On NRx Pharmaceuticals

Hedge funds and other institutional investors have recently modified their holdings of the company. Ethos Financial Group LLC purchased a new stake in shares of NRx Pharmaceuticals during the 3rd quarter worth $39,000. Sjbenen Advisory LLC acquired a new stake in NRx Pharmaceuticals in the fourth quarter valued at $41,000. One Wealth Management Investment & Advisory Services LLC raised its stake in NRx Pharmaceuticals by 86.1% in the third quarter. One Wealth Management Investment & Advisory Services LLC now owns 27,991 shares of the company’s stock valued at $92,000 after buying an additional 12,950 shares in the last quarter. Global Retirement Partners LLC purchased a new stake in NRx Pharmaceuticals during the 4th quarter worth about $107,000. Finally, Two Sigma Investments LP lifted its holdings in NRx Pharmaceuticals by 66.4% during the 3rd quarter. Two Sigma Investments LP now owns 52,332 shares of the company’s stock worth $173,000 after buying an additional 20,880 shares during the last quarter. 4.27% of the stock is currently owned by institutional investors and hedge funds.

NRx Pharmaceuticals Company Profile

NRx Pharmaceuticals, Inc is a clinical-stage specialty biopharmaceutical company focused on the development and repurposing of small-molecule therapeutics for central nervous system and rare disease indications. The company’s research strategy centers on advancing compounds with established safety profiles into new neurological and inflammatory conditions, leveraging translational science and biomarker-driven trial design to accelerate clinical development. NRx’s pipeline includes Ifenprodil, an NMDA receptor antagonist in investigation for acute respiratory distress syndrome and inflammatory muscle disorders, as well as investigational formulations targeting depressive and cognitive disorders.

Since securing global rights to its lead assets, NRx has initiated multiple proof-of-concept studies in the United States and Europe, collaborating with academic institutions and clinical research organizations to evaluate safety and efficacy across a range of indications.